home / stock / orph / orph quote
Last: | $0.87 |
---|---|
Change Percent: | -2.25% |
Open: | $0.906 |
Close: | $0.87 |
High: | $0.9571 |
Low: | $0.8457 |
Volume: | 763,915 |
Last Trade Date Time: | 03/30/2022 04:55:01 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.87 | $0.906 | $0.87 | $0.9571 | $0.8457 | 763,915 | 03-30-2022 |
$0.89 | $0.8423 | $0.89 | $0.96 | $0.8275 | 1,092,073 | 03-29-2022 |
$0.84 | $0.8925 | $0.84 | $0.8925 | $0.8291 | 370,491 | 03-28-2022 |
$0.8917 | $0.87 | $0.8917 | $0.8975 | $0.8622 | 309,174 | 03-25-2022 |
$0.9144 | $0.91 | $0.9144 | $0.9275 | $0.8734 | 674,107 | 03-24-2022 |
$0.892 | $0.83 | $0.892 | $0.97 | $0.8276 | 1,562,668 | 03-23-2022 |
$0.8247 | $0.772 | $0.8247 | $0.85 | $0.77 | 869,425 | 03-22-2022 |
$0.8448 | $0.8345 | $0.8448 | $0.87 | $0.8131 | 947,129 | 03-21-2022 |
$0.88 | $0.89 | $0.88 | $0.9 | $0.8002 | 2,630,870 | 03-18-2022 |
$0.9 | $0.83 | $0.9 | $1 | $0.76 | 15,528,529 | 03-17-2022 |
$0.655 | $0.59 | $0.655 | $0.69 | $0.59 | 1,137,894 | 03-16-2022 |
$0.565 | $0.6155 | $0.565 | $0.62 | $0.5451 | 693,815 | 03-15-2022 |
$0.6155 | $0.62 | $0.6155 | $0.649 | $0.5101 | 2,999,452 | 03-14-2022 |
$0.6836 | $0.7443 | $0.6836 | $0.8294 | $0.65 | 5,729,316 | 03-11-2022 |
$1.26 | $1.23 | $1.26 | $1.372 | $1.2 | 1,423,360 | 03-10-2022 |
$1.19 | $1.18 | $1.19 | $1.19 | $1.15 | 202,374 | 03-09-2022 |
$1.14 | $1.13 | $1.14 | $1.17 | $1.09 | 248,014 | 03-08-2022 |
$1.14 | $1.09 | $1.14 | $1.19 | $1.04 | 371,006 | 03-07-2022 |
$1.09 | $1.16 | $1.09 | $1.19 | $1.09 | 320,960 | 03-04-2022 |
$1.17 | $1.22 | $1.17 | $1.22 | $1.17 | 214,648 | 03-03-2022 |
News, Short Squeeze, Breakout and More Instantly...
Orphazyme A/S Company Name:
ORPH Stock Symbol:
NASDAQ Market:
(NewsDirect) hVIVO PLC (AIM:HVO) chief executive Yamin 'Mo' Khan discusses the company's record-breaking financial results in 2023 in an interview with Proactive's Stephen Gunnion. hVIVO announced a 16% year-on-year growth in revenue, reaching £56 million, with an EBITDA margin i...
(NewsDirect) hVIVO chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss the sale of shares in hVIVO PLC by directors, including himself. Friel explained his decision to sell a portion of his shares in hVIVO was to accommodate the high demand from major institutions whil...
(NewsDirect) hVIVO PLC (AIM:HVO) Chief Scientific Officer Andrew Catchpole speaks to Steve Darling from Proactive after the specialist contract research organisation announced it has secured a £6.3 million contract with a biotechnology client for the testing of their antiviral candid...